Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 1 · ActiveModality: oral small molecule (allosteric GCase modulator)
Aliases GT-02287
Target GCase (glucocerebrosidase)
Partnerships Minoryx Therapeutics: exclusive worldwide license to Magellan platform/STAR compounds (Dec 2017); royalty-bearing; term 10 years post first commercialization
Indications
Parkinson's disease with GBA1 mutation(Phase 1)
Parkinson's disease without GBA1 mutation(Phase 1)
Catalysts
— Q3 2026
— October 2026
Status note Lead candidate; Phase 1a in healthy volunteers complete; Phase 1b in people with Parkinson's ongoing (Part 1 complete; Part 2 extension ongoing). FDA IND authorized June 2026 for Phase 2a.
GT-04686
Preclinical · ActiveModality: oral small molecule (allosteric GCase modulator)
Target GCase (glucocerebrosidase)
Partnerships Minoryx Therapeutics: same Magellan platform license
Indications
not disclosed(Preclinical)
Status note Structurally distinct series of allosteric GCase modulators; ready to advance into IND-enabling studies. Indication not stated.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.